This site is intended for healthcare professionals

Genentech announces new data reinforcing the long-term benefit of Venclexta-based combinations for relapsed or refractory chronic lymphocytic leukemia.

Read time: 2 mins
Last updated:7th Dec 2020
Published:7th Dec 2020
Condition: Chronic Lymphocytic Leukemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest